Friday, November 2, 2012

"Tough as Hell: Power in Pink"

This young woman's story is a must read! Genetic testing for breast cancer at age 27.

Here's an excerpt:
"Although some people may think finding out they have a genetic predisposition would be devastating, in my family, we view it as something positive. It gave us advanced warning of something that could cause our family harm and is how I caught my cancer early."

http://ireport.cnn.com/docs/DOC-851205


Read more!

Thursday, October 25, 2012

Tests for Herediatry Colon Cancer are Underutilized

Visit Bloomberg News to read about the availability, and unfortunate under-utilization, of genetic testing for hereditary colon, uterine, ovarian and GI cancers.

http://www.bloomberg.com/news/2012-10-24/life-saving-dna-test-overlooked-in-rise-of-colon-cancer.html Read more!

Tuesday, September 25, 2012

ACLU and PUBPAT Ask Supreme Court to Rule that Patents on Breast Cancer Genes Are Invalid

A federal district court previously invalidated all of the challenged BRCA patents. However, in August, a federal appeals court ruled for the second time that companies can obtain patents on the genes.

“In our view, the court of appeals did not fully consider or correctly apply the Supreme Court’s most recent and relevant patent law decisions," said Chris Hansen, staff attorney with the ACLU. “DNA occurs naturally in the human body and cannot be patented by a single company that can then use its patents to limit scientific research and the free exchange of ideas.”

Visit: http://www.aclu.org/womens-rights/aclu-and-pubpat-ask-supreme-court-rule-patents-breast-cancer-genes-are-invalid to read more! Read more!

Friday, September 14, 2012

Monday, September 10, 2012

Read more!

If you are considering genetic testing - be seen by a Genetic Counselor or other Genetics Professional. Here's why:

An excerpt from Bloomberg.com

Fumbled DNA Tests Mean Peril for Breast-Cancer Patients
By Robert Langreth - Sep 10, 2012 12:00 AM ET

Debbie McCarron was prepared to get both of her breasts taken off if a blood test in December 2006 revealed she carried a gene that vastly increases the risk of breast cancer. Having survived the disease five years earlier, she didn’t want to risk getting it again.

To her relief, her oncologist told her the test, done by Myriad Genetics Inc. (MYGN), had come back negative, “just like I knew it would,” McCarron recalls her doctor saying.

He was wrong. The results, in fact, were positive. McCarron didn’t learn this, though, until July 2009, more than two years later, when a genetic counselor reviewed the test following McCarron’s surgery to remove a new malignant breast tumor. Since then, her oncologist, Haresh Jhangiani, told Bloomberg he isn’t clear about what happened.

Read more at: http://www.bloomberg.com/news/2012-09-10/fumbled-dna-tests-mean-peril-for-breast-cancer-patients.html Read more!

Monday, August 27, 2012

Genetic Counseling and Testing in Our Community

Ms. Berges is passionate about spreading the word - know your maternal and paternal family history and seek genetic counseling for an evaluation of your hereditary risk. Click here to read more about Ms. Berges' story: http://nhregister.com/articles/2012/08/24/life/doc5038081087aa9058601311.txt?viewmode=fullstory Read more!

Monday, August 20, 2012

Will Insurers Cover $700 for Myriad's Large Rearrangement Test Plus $3K for BRACAnalysis?

GenomeWeb features Ellen T. Matloff, MS in the conversation about "comprehensive BRCA" testing. Click on the above light blue link to view the full article at genomeweb.com

Expert from genomeweb.com

"Matloff acknowledged that NCCN support for BART testing should spur more coverage for the test, but she took issue with Myriad's business ethics. "Not including an essential part of the test in what they call Comprehensive BRACAnalysis [is] absolutely unacceptable," she said. "Now that the NCCN guidelines have backed up what all of us have said — that every patient who is a candidate for BRACAnalysis should also have BART — I think what the right thing to do would have been to combine this into one test."

Well before NCCN recommended BART, healthcare providers and patient advocates were urging Myriad to fold BART into BRACAnalysis as a single offering. Last year, after Myriad released data showing that a certain portion of deleterious mutations are missed by standard BRCA testing, a group of 200 genetics professionals, surgeons, oncologists, and nurses led by the Yale Cancer Center wrote an open letter to the company asking it to incorporate this large rearrangement analysis into its Comprehensive test at no additional cost (PGx Reporter 8/3/2011). "We wanted BART to be a part of BRACAnalysis but [Myriad] ignored that," Matloff said.

Even if most insurers cover BART testing, ultimately the decision is up to the patient and the doctor as to whether to order the additional diagnostic. The fact that Comprehensive BRACAnalysis doesn't include BART could result in confusion among healthcare providers and cause them to believe that the original test covers all the important markers associated with breast and ovarian cancer susceptibility.

"Despite the fact that improvements in genetics technology have dramatically reduced the cost of performing genetic testing, Myriad's price for this test has continued to go up further," Sue Friedman, executive director of the patient advocacy group Facing Our Risk of Cancer Empowered, told PGx Reporter over e-mail. "Further, I fear that women undergoing 'Comprehensive BRCA testing,' which does not include BART, could mistakenly think they had complete BRCA testing. It is unconscionable that Myriad is providing the test in two separate parts in order to gain maximum reimbursement."" Read more!

Tuesday, August 7, 2012

Adverse Events in Cancer Genetic Testing: Medical, Ethical, Legal, and Financial Implications

AdverseEvents Part 2
Read more!

Thursday, August 2, 2012

Adverse Events in Cancer Genetic Testing: Medical, Ethical, Legal and Financial Implications

Listen to our genetic counselors Ellen Matloff, MS, CGC and Karina Brierley, CGC discuss their recent publication “Adverse Events in Cancer Genetic Testing: Medical, Ethical, Legal and Financial Implications”. This publication presents a national series of cases illustrating errors resulting from cancer genetic counseling and testing performed by clinicians without specialization in genetics and the resulting impact on medical liability, health care costs, the patients and their families.

Click here to be directed to the July 29, 2012 recording. Read more!